LOGC - Mergers and acquisitions

OAKLAND, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- ContextLogic Holdings Inc. (OTCQB:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the first quarter ended March 31, 2026. Basis of Presentation  ContextLogic completed the acquisition of US Salt on February 26, 2026. To reflect the basis difference as a result of the US Salt acquisition, GAAP results for the first quarter of 2026 are presented in two parts: the period from January 1, 2026 through February 26, 2026 ("Predecessor"), reflecting legacy US Salt, and the period from February 27, 2026 through March 31, 2026 ("Successor"), reflecting ContextLogic Holdings Inc. and US Salt on a consoli

OAKLAND, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- ContextLogic Holdings Inc. (OTCQB:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the fourth quarter and fiscal year ended December 31, 2025. Company Update Subsequent to the end of the fourth quarter 2025, the Company completed the acquisition of US Salt Parent Holdings, LLC and its subsidiaries (together, "US Salt"), marking a pivotal milestone in ContextLogic's evolution into a business ownership platform. The Company remains focused on identifying and pursuing additional acquisitions of businesses that are niche, competitively advantaged, and built for long-duration value creation. Four

As per the report by Visiongain, the Rare Diseases Market was valued at US$188.58 billion in 2022 and is projected to grow at a CAGR of 12.27% during the forecast period 2023-2033.  Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact

Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact Analysis and Recovery Pattern Analysis ("V"-shaped, "W"-shaped, "U"-shaped, "L"-shaped), Profiles of Leading Companies, Region and Country.  The rare diseases market was valued at

Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact Analysis and Recovery Pattern Analysis ("V"-shaped, "W"-shaped, "U"-shaped, "L"-shaped), Profiles of Leading Companies, Region and Country.  The rare diseases market was valued a